Akèy › Kansè gastro-intestinal › Massachusetts › Boston
Etid klinik pou Kansè gastro-intestinal nan Boston, MA
15 etid pou Kansè gastro-intestinal ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Ap rekriteFaz 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Ap rekriteFaz 3
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Ap rekriteFaz 3
- GSK Investigational Site, Boston
- GSK Investigational Site, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
SURGE: Supporting Utility and Representation in Genomics-based Cancer Trial Enrollment (Intervention)
Ap rekrite
- Dana Farber Cancer Institute, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
Ap rekrite
- Dana-Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Ap rekriteFaz 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Ap rekriteFaz 1
- Dana-Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital Cancer Center, Boston
BOLSTER: Learning New Skills to Thrive
Ap rekrite
- Dana-Farber Cancer Institute, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Ap rekriteFaz 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Ap rekriteFaz 1/2
- Massachusetts General Hospital,, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Dana Farber Cancer Institute, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Massachusetts General Hospital, Boston
Etid Kansè gastro-intestinal nan lòt vil
- Houston, TX21 etid
- New York City, NY12 etid
- Nashville, TN10 etid
- Los Angeles, CA9 etid
- Durham, NC8 etid
- Dallas, TX8 etid
- Baltimore, MD8 etid
- Cincinnati, OH8 etid
- Arlington, VA8 etid
- San Antonio, TX7 etid
- Baldwin Park, CA7 etid
- Seattle, WA7 etid
Lòt etid nan Boston
- Kansè nan tete111 etid
- Kansè Poumon ki pa ti selil90 etid
- Kansè (tout kalite)86 etid
- Kansè kolorektal63 etid
- Kansè Metastatik63 etid
- Kansè poumon62 etid
- Kansè ovè61 etid
- Kansè pwostat59 etid
- Depresyon52 etid
- Kansè Endomèt50 etid
- Ensifizyans kadyak44 etid
- Leksemi mieloïd egi44 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.